ArticleBMC cancer2025
Clinical characteristics and treatment of EGFR exon 19 L747 mutation in advanced NSCLC: a retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study investigates the clinical characteristics, targeted therapy outcomes, co-mutations, and prognosis of lung cancer patients with EGFR exon 19 (ex19) L747 mutations in Northwest China, providing insights for treating these rare mutations.
methodsWe retrospectively analyzed advanced NSCLC patients with EGFR ex19 L747 mutations, identified from January 2020 to August 2024 at Xijing Hospital, using next-generation sequencing for mutation detection. Comprehensive clinical data, including molecular profiles, treatment regimens, and efficacy, were evaluated, accompanied by three illustrative case studies.
resultsAmong ten patients (70.0% female, median age 56.5 years, 80.0% nonsmokers), three had L747P and seven had L747_P753delinsS mutations. Common co-mutations included TP53 (50.0%), RB1 (10.0%), MED12 (10.0%), BRCA1 (10.0%), SMARCA4 (10.0%), and HER2 (10.0%). Treatment involved EGFR-TKIs combined therapy, achieving an objective response rate (ORR) of 20.0%, median progression-free survival (mPFS) of eight months (95% CI, 5-not reached), and median overall survival (mOS) of 32 months (95% CI, 21-not reached). In the L747_P753delinsS group (n = 7), third-generation EGFR-TKIs produced one CR, with an ORR of 14.3%, mPFS of 12 months (95% CI, 6-not reached), and mOS not reached (95% CI, 23.3-not reached). Two L747P patients with TP53 co-mutations receiving afatinib showed PFS of 1.5 and 15 months; those with L747_P753delinsS mutations and TP53 co-mutations on third-generation EGFR-TKIs had PFS of 12 and 16 months.
conclusionsEGFR ex19 L747 mutations, particularly L747P, are rare and exhibit heterogeneous responses to varying generations of EGFR-TKIs. L747P shows limited response to first- and third-generation TKIs but improved outcomes with afatinib. L747_P753delinsS mutations favor third-generation TKIs. Larger studies are needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.